A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma

NCT06920901 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: APG777
DRUG: Placebo

Sponsor

Apogee Therapeutics, Inc.